Inogen Inc. Files 8-K: Board Changes and Executive Compensation Updates
Ticker: INGN · Form: 8-K · Filed: Feb 3, 2025 · CIK: 1294133
| Field | Detail |
|---|---|
| Company | Inogen Inc (INGN) |
| Form Type | 8-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $45,000, $5,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, regulation-fd
Related Tickers: INGN
TL;DR
Inogen Inc. (INGN) filed an 8-K on Jan 30, 2025, reporting board changes and executive comp updates.
AI Summary
On January 30, 2025, Inogen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of new directors and updates to compensatory arrangements for certain officers. It also covers Regulation FD disclosures and financial statements.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can indicate internal shifts that may affect company direction and performance.
Key Players & Entities
- Inogen Inc. (company) — Registrant
- January 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 859 Ward Drive, Goleta, California 93111 (address) — Principal Executive Offices
- (805) 562-0500 (phone_number) — Registrant's Telephone Number
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of new directors and potentially the departure of others, though specific names are not detailed in the provided excerpt.
What is the nature of the updates to compensatory arrangements?
The filing mentions updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not provided in this excerpt.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is January 30, 2025.
What is Inogen Inc.'s principal executive office address?
Inogen Inc.'s principal executive office is located at 859 Ward Drive, Goleta, California 93111.
What is the SIC code for Inogen Inc.?
The Standard Industrial Classification (SIC) code for Inogen Inc. is 3842, which pertains to Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Filing Stats: 1,149 words · 5 min read · ~4 pages · Grade level 10.2 · Accepted 2025-02-03 16:22:20
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value INGN The Nasdaq Stock Mar
- $45,000 — led to receive the following cash fees: $45,000 per year for service as a member of the
- $5,000 — or service as a member of the Board and $5,000 per year for service as a member of eac
Filing Documents
- ingn-20250130.htm (8-K) — 53KB
- ingn-ex99_1.htm (EX-99.1) — 16KB
- img132417817_0.jpg (GRAPHIC) — 9KB
- 0000950170-25-012334.txt ( ) — 198KB
- ingn-20250130.xsd (EX-101.SCH) — 24KB
- ingn-20250130_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On February 3, 2025, the Company issued a press release announcing Ms. Sahney's appointment as a director. A copy of the press release is furnished herewith as Exhibit 99.1. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated February 3, 2025. 104 The cover page of this Current Report on Form 8-K, formatted in inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOGEN, INC. Date: February 3, 2025 By: /s/ Michael Bourque Michael Bourque Executive Vice President Chief Financial Officer Treasurer